Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice

Prime-Boost Immunization Strategies against Chikungunya Virus

“…The ASR is thought to play a critical role in regulating CHIKV virulence and regeneration (54,55). Interestingly, these data conform to earlier reports, from investigations of CHIKV-infected humans, nonhuman primates, and mice (30,49,52), that neutralizing antibodies tend to target this region. The other prominent regions identified, region 2 (amino acids 3113 to 3138) and region 3 (amino acids 3185 to 3210), cluster at the C terminus of the E2 glycoprotein.…”

“…Here we examined the immunogenicity and efficacy of p62-E1 protein in the C57BL/6 mouse infection model (12,55) and showed that two immunizations with p62-E1 mixed with the AS03 or Matrix-M adjuvant were required to induce immunity against CHIKV challenge. The Matrix-M adjuvant elicited the highest magnitudes of anti-CHIKV IgG titers, and as in a recent preclinical study with an influenza virus antigen, formulation with Matrix-M induced a balanced IgG1/IgG2c ratio (52). This is in contrast to the AS03 adjuvant, which induced an IgG2c-tilted antibody profile.…”

“…This result may also depend on the quantity rather than the quality of the specific antibody response. All epitopes recognized lie within the CHIKV E2 glycoprotein (30,49,52). Collectively, these studies accentuate the importance of CHIKV E2 glycoprotein and its immunodominance in eliciting neutralizing antibodies.…”

Matrix MTMadjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4+T cell responses in man

“…This finding in humans confirms the balanced T helper response we observed for these vaccines in murine studies. 14,23,29 In murine studies of adjuvanted influenza vaccines, Matrix-M™, induced significantly higher both Th1 and Th2 cytokine response than observed after AS03 or alum formulations. 29 GM-CSF production was also elicited upon influenza-stimulation in all Matrix M TM adjuvanted groups, GM-CSF has adjuvant properties 30 and the adjuvant effect of Matrix M TM could partly rely on induction of GM-CSF.…”

Fourth International Conference: Modern Vaccines/Adjuvants Formulation—Impact On Future Development

“…When combined with influenza Ags (from the commercially available split vaccine Vaxigrip ® , Sanofi Pasteur), Matrix M™ induced a balanced Th1/Th2 (IFNγ, IL-2, -4, -5, and -10) cellular as well as a good humoral (IgG1 and IgG2a) responses, at least as good or sometime stronger than the other adjuvants tested in their model (Alum and AS03). 19 Very interestingly, Matrix-M™ has already been included and evaluated in several phase I clinical trials; study on vaccination against pandemic influenza in adult (PanFluVac virosomal HA adjuvanted in Matrix-M™) 20 and study on vaccination against seasonal influenza in elderly (Vaxigrip ® adjuvanted in Matrix-M™). 21 Both studies show good safety profile for Matrix-M™ (only mild and transient Adverse Events [AE] were reported), good immunogenicity and dose-sparing effects.…”